Who Owns Eloxatin?
Eloxatin (oxaliplatin) is owned by Sanofi, a publicly traded French pharmaceutical company headquartered in Paris. Sanofi trades on Euronext Paris (SAN) and NASDAQ (SNY). The FDA approved Eloxatin in 2002 for colorectal cancer treatment. The drug's U.S. patent expired in August 2022, and generic oxaliplatin is now widely available. Sanofi generated approximately $44.7 billion in revenue in 2025.
Eloxatin Timeline
Who Owns Eloxatin?
- Parent Company: Sanofi
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: Euronext Paris: SNY
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Eloxatin | Sanofi | Wholly owned |
History of Eloxatin
- Founded: 2002
- Founders: Sanofi (in-licensed from Yakult Honsha)
Oxaliplatin was first synthesized in the 1970s by researchers at Nagoya City University in Japan. The compound belongs to a class of platinum-based chemotherapy drugs that includes cisplatin and carboplatin. Unlike earlier platinum compounds, oxaliplatin was designed to have a different toxicity profile and to be effective against certain cisplatin-resistant tumors.
Yakult Honsha, the Japanese food and pharmaceutical company, acquired the rights to oxaliplatin and conducted early clinical trials in Japan. Sanofi-Synthelabo (which merged with Aventis in 2004 to form Sanofi-Aventis, later renamed Sanofi) in-licensed the compound for development outside Japan. The European Medicines Agency approved Eloxatin in 1999 for the treatment of metastatic colorectal cancer.
The FDA approved Eloxatin on August 9, 2002, for use in combination with 5-fluorouracil and leucovorin (the FOLFOX regimen) for the treatment of metastatic colorectal cancer. In 2004, the FDA granted additional approval for Eloxatin as adjuvant therapy after surgical resection of stage III colon cancer, based on the MOSAIC trial which demonstrated improved disease-free survival.
Eloxatin became one of Sanofi's most important oncology products, with peak annual sales reaching approximately $2.3 billion in 2006. The drug was a standard component of colorectal cancer treatment regimens worldwide. However, sales declined as generic competition entered European markets starting in 2006 and as newer targeted therapies became available.
In the United States, Eloxatin faced multiple patent challenges from generic manufacturers. Sanofi reached patent litigation settlements with several generic companies, including Hospira (now Pfizer) and Sun Pharma, which allowed limited generic entry before the full patent expiration. The core U.S. patent for Eloxatin expired in August 2022, opening the market to full generic competition. Generic oxaliplatin is now widely available from multiple manufacturers including Fresenius Kabi, Sandoz (Novartis), and Pfizer.
About Sanofi
Sanofi is a publicly traded French multinational pharmaceutical company founded in 1973, headquartered in Paris, France. The company trades on Euronext Paris under ticker SNY and reported FY2025 net sales of €43.63 billion, up 9.9 percent at constant exchange rates, with business EPS of €7.83, up 15.0 percent. Growth was driven by Dupixent (€15.7 billion in FY2025 sales, up 25.2 percent). Sanofi operates as a single Biopharma segment with approximately 74,846 employees worldwide. CEO Paul Hudson departed in February 2026, with Belén Garijo appointed as new CEO effective April 29, 2026.
- Founded: 1973
- Headquarters: Paris, France
- Company Type: Publicly Traded
- Stock: Euronext Paris: SNY
- Revenue: €43.63 billion (FY2025), up 9.9 percent at constant exchange rates
- Employees: Approximately 74,846
Where Is Eloxatin Made / Based?
- Headquarters: Paris, France
- Manufacturing / Operations: France, United States
Eloxatin Categories & Tags
Eloxatin Recalls & Controversies
Eloxatin has faced several notable issues during its market history:
Patent Litigation: Sanofi engaged in extensive patent litigation to protect Eloxatin from generic competition in the United States. In 2007, Sanofi reached settlements with several generic manufacturers that allowed limited generic entry. The settlements were reviewed by the Federal Trade Commission for potential antitrust violations. The core patent expired in August 2022, ending all exclusivity.
Neurotoxicity Concerns: Eloxatin carries a boxed warning for anaphylaxis and is known to cause peripheral neuropathy, a dose-limiting side effect. Two types of neuropathy are associated with oxaliplatin: an acute, cold-triggered neuropathy that occurs during or shortly after infusion, and a chronic cumulative neuropathy that can persist after treatment ends. These side effects are well-characterized and reflected in the prescribing information.
Vial Shortage: In 2010, Sanofi experienced a manufacturing shortage of Eloxatin that led to supply constraints in the United States. The FDA worked with Sanofi to address the shortage, and the company implemented allocation measures to ensure continued supply to patients.
Brands Owned by Sanofi
Healthcare PharmaceuticalsAubagio
Owned by Sanofi
Sanofi Genzyme's oral disease-modifying therapy (teriflunomide) for relapsing forms of multiple sclerosis, FDA approved September 12, 2012, that works by inhibiting dihydroorotate dehydrogenase (DHODH) to selectively reduce proliferating lymphocytes driving MS inflammation.
multiple-sclerosisteriflunomidedhodh-inhibitor
Healthcare PharmaceuticalsCervarix
Owned by Sanofi
Bivalent HPV vaccine targeting HPV types 16 and 18, developed by GSK. Discontinued in most markets as part of GSK portfolio rationalization.
vaccinehpvcancer-prevention
Healthcare PharmaceuticalsDupixent
Owned by Sanofi
Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.
immunologyatopic-dermatitisdupilumab
Healthcare PharmaceuticalsLantus
Owned by Sanofi
Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition eroded its market share.
diabetesinsulin-glarginetype-1-diabetes
Healthcare PharmaceuticalsLemtrada
Owned by Sanofi
Sanofi Genzyme's high-efficacy anti-CD52 monoclonal antibody (alemtuzumab) for active relapsing-remitting multiple sclerosis, FDA approved November 14, 2014, reserved for patients with inadequate response to two or more disease-modifying therapies due to its serious risk profile and REMS program.
multiple-sclerosisalemtuzumabanti-cd52
Healthcare PharmaceuticalsLovenox
Owned by Sanofi
Sanofi anticoagulant brand (enoxaparin sodium), FDA approved in 1993 for preventing and treating blood clots including DVT and pulmonary embolism.
cardiovascularenoxaparinanticoagulant
Eloxatin Ownership: Pros & Cons
Advantages
- +Proven efficacy in colorectal cancer treatment as part of FOLFOX and CAPOX regimens
- +Backed by Sanofi's manufacturing quality standards and global distribution
- +Well-established safety profile with known, manageable side effects
- +Included in clinical guidelines for colorectal cancer treatment worldwide
- +Generic availability provides cost-effective access to the same active ingredient
Considerations
- -U.S. patent expired in August 2022, eliminating market exclusivity
- -Generic oxaliplatin has largely replaced branded Eloxatin in clinical use
- -Peripheral neuropathy is a significant dose-limiting side effect
- -Requires intravenous administration in a clinical setting
- -No longer a material revenue contributor for Sanofi
- -Newer targeted therapies and immunotherapies are changing colorectal cancer treatment
Frequently Asked Questions About Eloxatin
Sources & Further Reading
- Sanofi Corporate Website -
- FDA Eloxatin Prescribing Information -
- American Society of Clinical Oncology -
- National Cancer Institute -
- SEC EDGAR: Sanofi (SNY) -
- Euronext Paris: Sanofi (SAN) -
- MOSAIC Trial, New England Journal of Medicine (2004) -
- ClinicalTrials.gov: Oxaliplatin Studies -
- Colorectal Cancer Alliance -
Where to Buy
Disclosure: We may earn commission from purchases
Eloxatin on AmazonCompetitors to Eloxatin
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | Multiple manufacturers (generic drug) | 1952 | Mass market | Global | All-ages | |
| Roche | USA (Genentech) | 1998 | Mass market | Global | All Genders | |
| Sanofi | France | 1996 | Established | Global | Unisex |
Learn More About Competitors
Healthcare PharmaceuticalsLeucovorin
Owned by Pfizer Inc.
Generic prescription folinic acid (5-formyltetrahydrofolate) used for methotrexate rescue in high-dose methotrexate chemotherapy, as a biochemical modulator of fluorouracil (5-FU) in colorectal cancer regimens including FOLFOX and FOLFIRI, and for treatment of megaloblastic anemia; originally developed by Lederle Laboratories in the 1940s and now manufactured by multiple pharmaceutical companies including Pfizer/Hospira, Teva, and Fresenius Kabi.
folinic-acidmethotrexate-rescuecolorectal-cancer
Healthcare PharmaceuticalsXeloda
Owned by Roche
Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech, FDA approved April 30, 1998, as the first oral chemotherapy for metastatic breast cancer and later for metastatic colorectal cancer, now available as generic capecitabine following patent expiration.
oncologycapecitabineoral-chemotherapy
Healthcare PharmaceuticalsTaxotere
Owned by Sanofi
Prescription chemotherapy drug (docetaxel) for breast and other cancers, owned by Sanofi. Subject of permanent alopecia litigation.
oncologychemotherapybreast-cancer
Competitive Analysis
Market Positioning: Eloxatin competes with 3 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Eloxatin
Looking for brands with different ownership structures? These similar brands are not owned by Sanofi, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Eloxatin which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Eloxatin which is under a publicly traded parent company.
Healthcare PharmaceuticalsAlcon
Owned by Alcon Inc.
Independent publicly traded global eye care company headquartered in Geneva, Switzerland, specializing in surgical equipment, contact lenses, and ophthalmic products. Spun off from Novartis in April 2019.
eye-carecontact-lensesophthalmic
Publicly Traded
Alcon operates independently without a large parent corporation.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsGoodRx
Owned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
prescription-savingshealthcare-technologydrug-prices
Publicly Traded
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Sanofi Stock Information
Jobs at Sanofi
Latest News About Eloxatin
Related Articles About Eloxatin
View more articles
Guides
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Who Brands StaffFeb 4, 2026
PharmaceuticalBrand OwnershipHealthcare
Consumer Education
Why Younger Consumers Research Brand Ownership Before Buying
72% of Gen Z trust customer reviews over influencer content. 94% of brands score lower on trust with Gen Z. Discover why younger consumers research brand ownership before buying. Explore our database.
Who Brands StaffAug 22, 2026
Gen ZMillennialsBrand Ownership
Consumer Education
How Brand Transparency Is Changing Consumer Behaviour
60% of consumers actively avoid products with untrustworthy origins. 72% say supply chain transparency increases trust. 63% demand better transparency from brands. Discover how transparency is changing consumer behaviour. Explore our database.
Who Brands StaffAug 21, 2026
TransparencyConsumer BehaviourSupply Chain
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment
Brandcontact-lenses
Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.
Brand in Healthcare & Pharmaceuticals
vision-carejohnson-and-johnson